Jeff Szer
HAEMATOLOGIST
Haematology
The Peter MacCallum Cancer Centre
Australia
Biography
Professor Szer has particular expertise in malignant haematology and haemopoietic stem cell transplantation, which he established as a form of therapy in Vicotria in the early 1980s.. He is a recognised key opinion leader in the rare non-malignant disorders paroxysmal nocturnal haemoglobinuria and Gaucher disease. He is a member of the Medical and Scientific Advisory Group of Myeloma Australia and is President of the Worldwide Network for Blood and Marrow Transplantation. He has been Director of the Western ad Central Melbourne Integrated Cancer Service since 2009. He has also been Editor in Chief of Internal Medicine Jounral since 2005 and is ont he editorial board of several other international journals.
Research Interest
Expertise in malignant haematology and haemopoietic stem cell transplantation
Publications
-
Pastores GM, Petakov M, Giraldo P, Rosenbaum H, Szer J, Deegan PB, Amato DJ, Mengel E, Tan ES, Chertkoff R, Brill-Almon E, Zimran A. A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase. Blood Cells Mol Dis. 2014;53:253-260
-
Aljurf M, Rizzo JD, Mohty M, Hussain F, Madrigal A, Pasquini MC, Passweg J, Chaudhri N, Ghavamzadeh A, El Solh H, Atsuta Y, Szer J, Kodera Y, Niederweiser D , Gratwohl A, Horowitz MM. Challenges and opportunities for outcomes registries; Perspectives from international HSCT Registries experts. Bone Marrow Transplant. 2014;49:1016-1021
-
Hillmen P, Muus P, Röth A, Elebute MO, Risitano AM, Schrezenmeier H, Szer J, Browne P, Maciejewski JP, Schubert J, Urbano-Ispizua A, de Castro C, Socié G, Brodsky RA. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2013;162:62-73
